+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Malignant Melanoma: Update Bulletin

  • ID: 4521396
  • Newsletter
  • January 2020
  • Region: Global
  • FirstWord Publishing

Gain new key opinion leader (KOL) insights on the latest events happening in melanoma. Topics covered include expert opinions on; results of thePhase III EORTC1325/KEYNOTE-054 trial investigating pembrolizumab (Keytruda; Merck & Co.) as monotherapy for patients with surgically resected high-risk melanoma; views on the potential of Idera Pharmaceuticals’ IMO-2125, which has been granted Fast Track designation by the FDA in combination with ipilimumab for the treatment of patients with anti-PD-1 refractory metastatic melanoma; and views on the results of a Phase II study investigating Iovance Biotherapeutics’ LN-144 for the treatment of metastatic melanoma.

Business Questions:
  • Do KOLs anticipate the results of the EORTC1325/KEYNOTE-054 trial will result in uptake of pembrolizumab in the high-risk adjuvant setting?
  • How do KOLs expect pembrolizumab will compete with nivolumab (Opdivo; Bristol-Myers Squibb) and ipilimumab (Yervoy; BMS) in the adjuvant setting?
  • Do KOLs harbour any concerns regarding pembrolizumab’s safety profile?
  • How do KOLs view the results of IMO-2125’s Phase II study?
  • What advantages and disadvantages do KOLs identify with intralesional therapies such as IMO-2125 compared to systemic agents?
  • How do experts perceive the potential for use of IMO-2125 in the PD-1 refractory population?
  • How do KOLs perceive LN-144’s mechanism of action and preliminary trial results?
  • What are KOLs’ views on LN-144’s safety and tolerability profile compared to other melanoma treatments?
  • What concerns do the experts raise concerning the development of LN-144?
Note: Product cover images may vary from those shown